Benjamin F. Edwards & Company Inc. grew its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 11.2% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 28,804 shares of the biopharmaceutical company’s stock after purchasing an additional 2,908 shares during the period. Benjamin F. Edwards & Company Inc.’s holdings in Gilead Sciences were worth $2,039,000 at the end of the most recent reporting period.

Several other institutional investors have also recently modified their holdings of the company. Bank of New York Mellon Corp grew its position in shares of Gilead Sciences by 9.8% during the first quarter. Bank of New York Mellon Corp now owns 30,570,798 shares of the biopharmaceutical company’s stock valued at $2,076,368,000 after purchasing an additional 2,727,063 shares in the last quarter. Parnassus Investments CA grew its position in shares of Gilead Sciences by 37.4% during the first quarter. Parnassus Investments CA now owns 16,726,150 shares of the biopharmaceutical company’s stock valued at $1,110,228,000 after purchasing an additional 4,556,901 shares in the last quarter. APG Asset Management N.V. grew its position in shares of Gilead Sciences by 16.7% during the first quarter. APG Asset Management N.V. now owns 5,923,426 shares of the biopharmaceutical company’s stock valued at $402,319,000 after purchasing an additional 849,741 shares in the last quarter. AQR Capital Management LLC grew its position in shares of Gilead Sciences by 25.7% during the first quarter. AQR Capital Management LLC now owns 5,213,046 shares of the biopharmaceutical company’s stock valued at $354,070,000 after purchasing an additional 1,066,172 shares in the last quarter. Finally, Swiss National Bank grew its position in shares of Gilead Sciences by 26.9% during the first quarter. Swiss National Bank now owns 4,668,124 shares of the biopharmaceutical company’s stock valued at $317,059,000 after purchasing an additional 989,400 shares in the last quarter. Hedge funds and other institutional investors own 74.05% of the company’s stock.

GILD has been the subject of a number of research analyst reports. ValuEngine lowered Gilead Sciences from a “buy” rating to a “hold” rating in a research report on Friday, June 2nd. William Blair restated an “outperform” rating on shares of Gilead Sciences in a research report on Friday, June 16th. Vetr lowered Gilead Sciences from a “strong-buy” rating to a “buy” rating and set a $75.40 price objective for the company. in a research report on Wednesday, June 21st. BidaskClub upgraded Gilead Sciences from a “strong sell” rating to a “sell” rating in a research report on Thursday, June 22nd. Finally, Leerink Swann reiterated a “market perform” rating on shares of Gilead Sciences in a research report on Thursday, June 22nd. Eleven investment analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. Gilead Sciences currently has a consensus rating of “Buy” and a consensus price target of $83.06.

Gilead Sciences, Inc. (NASDAQ GILD) opened at 84.51 on Wednesday. Gilead Sciences, Inc. has a 52 week low of $63.76 and a 52 week high of $86.27. The company has a market cap of $110.36 billion, a P/E ratio of 9.18 and a beta of 1.19. The company has a 50-day moving average of $76.14 and a 200-day moving average of $69.83.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Wednesday, July 26th. The biopharmaceutical company reported $2.56 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $2.11 by $0.45. The company had revenue of $7.14 billion for the quarter, compared to analyst estimates of $6.35 billion. Gilead Sciences had a net margin of 42.90% and a return on equity of 66.07%. The firm’s quarterly revenue was down 8.2% on a year-over-year basis. During the same period in the prior year, the business earned $3.08 EPS. On average, equities research analysts predict that Gilead Sciences, Inc. will post $8.75 EPS for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Thursday, September 28th. Shareholders of record on Friday, September 15th will be issued a dividend of $0.52 per share. The ex-dividend date of this dividend is Thursday, September 14th. This represents a $2.08 dividend on an annualized basis and a yield of 2.46%. Gilead Sciences’s dividend payout ratio (DPR) is presently 22.58%.

ILLEGAL ACTIVITY NOTICE: “Gilead Sciences, Inc. (GILD) Shares Bought by Benjamin F. Edwards & Company Inc.” was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece on another domain, it was copied illegally and republished in violation of United States and international copyright and trademark laws. The legal version of this piece can be accessed at https://www.thecerbatgem.com/2017/09/13/gilead-sciences-inc-gild-shares-bought-by-benjamin-f-edwards-company-inc.html.

In other news, EVP Gregg H. Alton sold 25,000 shares of the firm’s stock in a transaction on Friday, September 1st. The shares were sold at an average price of $83.05, for a total value of $2,076,250.00. Following the sale, the executive vice president now directly owns 101,488 shares in the company, valued at approximately $8,428,578.40. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Robin L. Washington sold 51,820 shares of the firm’s stock in a transaction on Thursday, September 7th. The shares were sold at an average price of $85.00, for a total transaction of $4,404,700.00. Following the completion of the sale, the chief financial officer now owns 43,352 shares in the company, valued at $3,684,920. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 466,819 shares of company stock worth $36,740,240. 1.30% of the stock is owned by company insiders.

About Gilead Sciences

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Stock Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related stocks with our FREE daily email newsletter.